

October 26, 2015



Navidea Biopharmaceuticals to Announce Third Quarter 2015 Financial Results on November 4, 2015

- Conference call with investment community to follow at 8:30 a.m. EST -

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAV) today announced that the Company will report its financial results for the third quarter 2015, on Wednesday, November 4, 2015 prior to a conference call with the investment community scheduled at 8:30 a.m. EST.

Investors and the public are invited to access the live audio webcast through the link below. Participants who would like to ask questions during the question and answer session must participate by telephone also. Participants are encouraged to log-in and/or dial-in fifteen minutes before the conference call begins. The webcast replay is expected to be available on our investor website, <http://ir.navidea.com>, approximately two to four hours after the live event.

Event: Navidea Biopharmaceuticals Q3 2015 Financial Results Conference Call

Date/Time: Wednesday, November 4, 2015 at 8:30 a.m. EST

Webcast Link: <http://edge.media-server.com/m/p/apewz7w6/lan/en>

Dial-in Number – US: (855) 897-5884

Dial in Number – Int'l: (720) 634-2940

Conference ID Number: 64585280

Replay A webcast replay will be available on the Investor Relations section of our website at <http://ir.navidea.com> for 30 days.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAV) is a biopharmaceutical company focused on the development and commercialization of precision immuno-diagnostic agents and immuno-therapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea's first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel immuno-diagnostic agents and immuno-therapeutics, and advancing the Company's pipeline through global

partnering and commercialization efforts. For more information, please visit www.navidea.com.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20151026005453/en/>

Navidea Biopharmaceuticals

Investors

Tom Baker, 617-532-0624

tbaker@navidea.com

or

Media

Sharon Correia, 978-655-2686

Associate Director, Corporate Communications

Source: Navidea Biopharmaceuticals, Inc.